

Summary of status of development and availability of variant influenza A(H3N2) candidate vaccine viruses*

* Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)

7 November 2011 (*revised 6 January 2012¹*)

Candidate vaccine viruses

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Minnesota/11/2010	Wild type virus			CDC, USA
	NYMC X-203	Classical	New York Medical College, USA	NYMC, USA CDC, USA
	NYMC X-203A	Classical	New York Medical College, USA	NYMC, USA CDC, USA

Institutes contact details for candidate vaccine viruses orders/information:

CDC: rdonis@cdc.gov

NYMC: doris_bucher@nymc.edu

For general enquiries, please contact gisrs-whohq@who.int

For other candidate vaccine viruses and potency testing reagents, please go to <http://www.who.int/influenza/vaccines/virus/en/>

¹ Virus name changed following the joint FAO, OIE, WHO announcement of the standardization of terminology for the variant A(H3N2) virus recently infecting humans (http://www.who.int/influenza/gisrs_laboratory/terminology_ah3n2v/)